Lexagene Holdings: Top 10 Undervalued Medical Devices & Instruments Industry Stocks (LXG)
Lexagene Holdings is now ranked among the top 10 undervalued stocks in the Medical Devices & Instruments industry on the Toronto Stock Exchange or TSX Venture Exchange. A stock is considered undervalued if it trades at a discount to its valuation – a calculation used to determine the intrinsic (true) worth of a company. Valuation methodology provided by Stockcalc (see below).
Medical Devices & Instruments: Companies that develop, manufacture, and market medical and surgical equipment and machinery, including orthopedic products, respiratory care equipment, x-ray equipment, laser systems, implants, pacemakers, and other major medical machines and apparatus. Stocks in this category are held primarily for capital appreciation.
|Symbol||Name||Close Price ($)||Valuation ($)||Difference||Average Vol (30D)||Market Cap ($M)||Yield (%)||P/E Ratio|
|PINK-X||Perimeter Medical Imaging||1.64||3.16||1.52|
|NGMD-X||NuGen Medical Devices||0.06||0.07||0.01|
More about Lexagene Holdings
All data provided as-at market close September 29, 2022. The list is sorted by stocks with the greatest percentage difference between valuation and price. Lexagene Holdings Lexagene Holdings Inc is a biotechnology company. The principal business of The company is to research, develop and commercialize pathogen detection devices in the biochemical industry. Lexagene Holdings is listed under LXG on the TSX Venture Exchange.
StockCalc is a Canadian fintech company specializing in fundamental valuations for North American stocks and ETFs. StockCalc valuations (https://www.stockcalc.com/Resources) can help determine if a stock is undervalued. StockCalc's Weighted Average Valuation (WAV) is based on a proprietary calculation using model and analyst inputs, including: Discounted Cash Flow (DCF), Price & Other Comparables, Multiples, Adjusted Book Value (ABV) and Analyst Consensus
Artificial intelligence at Report on Business
Artificial Intelligence at Report on Business Report on Business scans market data using algorithms to process large quantities of information. The results are specialized reports produced through automation. Ongoing ROB project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities.